Literature DB >> 2959265

Influence of phosphodiesterase inhibition on myocardial energetics in dilative cardiomyopathy.

G Hasenfuss1, C Holubarsch, W H Heiss, T Bonzel, T Meinertz, H Just.   

Abstract

The effects of inhibition of phosphodiesterase by enoximone on left ventricular haemodynamics and myocardial energetics were investigated in 10 patients with idiopathic dilative cardiomyopathy. After intravenous administration of enoximone, there was a significant reduction of left ventricular systolic pressure from 126 +/- 21 to 93 +/- 16 mm Hg, of left ventricular end-diastolic pressure from 16 +/- 8 to 5 +/- 3 mm Hg and of left ventricular end-diastolic volume from 287 +/- 54 to 215 +/- 69 ml. Left ventricular pressure-volume work decreased significantly from 12.1 +/- 3.6 to 7.6 +/- 2.8 mm Hg.l. Heart rate was 87 +/- 17 before and 103 +/- 18 min-1 after administration of enoximone (p less than 0.01). Left ventricular systolic stress-time integral, a major determinant of myocardial oxygen consumption, decreased by 49% from 91 +/- 32 to 46 +/- 15 10(3) dyn.s/cm2 (p less than 0.01). In contrast myocardial oxygen consumption per beat was reduced by only 18%, from 138 +/- 28 to 113 +/- 17 microliters O2/100 g (p less than 0.01). The economy of myocardial contraction as calculated by the ratio of systolic stress-time integral to myocardial oxygen consumption per beat was 675 +/- 192 before and 370 +/- 128 dyn.s.100 g/cm2.microliter O2 after administration of enoximone. In conclusion, the phosphodiesterase inhibitor enoximone exhibits vascular and myocardial effects. The myocardial effects result in decreased economy of myocardial contraction. The possible molecular mechanisms of these energetic changes are discussed.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2959265     DOI: 10.1007/978-3-662-11289-2_39

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  2 in total

Review 1.  Enoximone. A review of its pharmacological properties and therapeutic potential.

Authors:  M W Vernon; R C Heel; R N Brogden
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

Review 2.  Phosphodiesterase inhibition by new cardiotonic agents: mechanism of action and possible clinical relevance in the therapy of congestive heart failure.

Authors:  H von der Leyen
Journal:  Klin Wochenschr       Date:  1989-06-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.